<DOC>
	<DOCNO>NCT02999906</DOCNO>
	<brief_summary>This multicenter , randomize ( 2:1 oral treprostinil : placebo ) , double-blind , placebo-controlled study subject Pulmonary Arterial Hypertension ( PAH ) currently receive background dual therapy ( ambrisentan , tadalafil ) least 30 day randomization PAH . Once randomize , subject return 5 study visit Week 28 blinded period . After Week 28 Visit , eligible subject transition open-label period study 20 week .</brief_summary>
	<brief_title>Study Compare Triple Therapy ( Oral Treprostinil , Ambrisentan , Tadalafil ) With Dual Therapy ( Ambrisentan , Tadalafil , Placebo ) Subjects With Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>1 . Between 18 79 year age , inclusive 2 . PAH idiopathic / heritable , PAH associate connective tissue disease , HIV infection , repair congenital systemictopulmonary shunt ( repair &gt; 1 year ) , appetite suppressant / toxin use 3 . Receiving dual therapy ( ambrisentan tadalafil ) 4 . Previous test ( e.g . right heart catheterization , echocardiography ) consistent diagnosis PAH 1 . Nursing pregnant 2 . PAH due condition note inclusion criterion 3 . Received PAHspecific drug therapy &gt; 2 year 4 . History uncontrolled sleep apnea , severe liver disease , severe renal impairment , leave sided heart disease , uncontrolled systemic hypertension 5 . Participated investigational drug device study within 90 day prior sign consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>PAH</keyword>
	<keyword>Oral Treprostinil</keyword>
	<keyword>dual therapy</keyword>
	<keyword>6 Minute Walk Test</keyword>
</DOC>